Valiant Organics Ltd

- Currently, Valiant Organics has term loans amounting to ₹113 crores and is not looking to take any further loans in the near future. - The company aims to continue repaying and reducing its debt as per the existing repayment schedule until FY '26. - Debt-free status is unlikely soon, as future big CAPEX may require additional term loans. - Cash flows are expected to improve once PAP ramp-up generates adequate accruals. - Regarding equity fundraising, specifically the IPO of Valiant Laboratories (formerly Bharat Chemicals), the management has not disclosed detailed information as discussions are ongoing and sensitive due to competitive reasons. - No explicit timelines or plans for the IPO or other equity fundraising were shared during the call.

- Pharma Intermediates project: CAPEX of around ₹80-85 crores has been committed; currently at pilot stage with scope to expand (Page 15). - PAP plant: Additional CAPEX planned to convert batch process into semi-continuous; CAPEX not significant (Page 17). - No major new CAPEX planned in near future; future large CAPEX possible 2-3 years down the line (Page 13, 6). - Current debt repayment plan ongoing until FY '26; future CAPEX may lead to additional term loans (Page 6). - Focus on ramping up existing projects like PAP and Pharma Intermediates rather than fresh large investments immediately (Page 6, 12). - Discussions ongoing on new product development and chlorination expansion, likely 2 years out (Page 13).

- PAP (Paracetamol raw material) production expected to ramp up from 400+ MT/month to around 800-900 MT/month, contributing 20-30% to total revenue in next 2-3 years. - FY '24 revenue guidance is flattish at around Rs. 900-950 crores due to subdued demand in dyes intermediates and ongoing ramp-up of Sarigam plant. - 20-25% growth anticipated in FY '24 driven by PAP ramp-up and pharma intermediates project becoming operational. - Focus on stabilizing and optimizing capacity utilization (80-85%) in existing and new plants like PAP and pharma intermediates over next 1-2 years. - Medium to long-term outlook positive with expected industry tailwinds (China plus 1 strategy, Indian specialty chemical sector growth). - Emphasis on expanding production capacity cautiously with efforts to improve asset turnover and margins around 18-22% EBITDA. - Pilot pharma intermediates plant expected to scale up commercially in about a year with utilization at 70-80%.

- FY '24 expected growth: 20%-25%, driven by PAP ramp-up and Pharma intermediates stabilization. - Operating margins targeted conservatively at 18%-20%, with long-term EBITDA margins projected between 20%-22%. - PAP production aims to reach optimal capacity (~800-900 MT/month), contributing 20%-22% to FY '24 revenue, potentially rising to 30% at full capacity. - Pharma Intermediates project (CAPEX ~Rs. 80-85 crores) currently in pilot stage with asset turns below 1x; expected to scale up within a year to 70%-80% utilization. - Asset turnover for Pharma project expected to improve post-pilot phase, but exact ratio uncertain due to campaign-based multi-product operation. - Debt reduction ongoing with no new loans planned near-term; cash flows expected to improve as projects stabilize. - Long-term focus on improving ROE from current lower levels to ~20% initially, with further enhancement over 2-3 years. - Revenue guidance for FY '24 is flattish, estimated Rs. 900-950 crores due to current market conditions and ramp-up timelines.

- The transcript does not provide specific details on the current or expected order book or pending orders for Valiant Organics Ltd. - Management mentions experimenting with product identification at the pharma intermediates pilot plant, indicating ongoing efforts to establish orders. - Demand outlook for key sectors such as dyes, pigments, and pharma intermediates is cautiously expected to improve in coming quarters, particularly for PAP and chlorination products. - Orders in the dyes and intermediates segment are currently subdued due to low industry demand and Eurozone challenges; improvement is expected in a quarter or two. - Most PAP production is supplied to a subsidiary making paracetamol, ensuring steady internal demand with around 10% sold externally. - No direct quantitative order book or pending orders information was discussed in the Q&A or management commentary.